VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
Summary
VERAXA Biotech reports new in vitro proof-of-concept data for its BiTAC-ADC platform. The company says the results support its tumor-restricted activation approach and reinforce its pipeline alongside the previously presented BiTAC-TCE program. VERAXA plans to use the BIO International Convention to discuss partnering opportunities around both platforms. The announcement follows the company’s recent NASDAQ listing and highlights its push toward next-generation antibody-based cancer therapies.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected